A Novel Approach to Immunotherapy
Gritstone is building a pipeline of personalized neoantigen immunotherapies for patients with the most difficult-to-treat solid tumors. We plan to initially focus on tumor types with the highest mutational burden including, but not limited to, non-small cell lung, gastric and bladder cancers. An Investigational New Drug (IND) application is planned for mid-2018 for a phase 1-2 clinical trial of a personalized neoantigen immunotherapy in combination with checkpoint inhibitors in patients with in the adjuvant and metastatic settings.
In addition to neoantigen therapy development, Gritstone is leveraging its unique antigen discovery platform to define targets for shared antigen immunotherapies, which would provide an opportunity to treat even more patients.